FDA alignment de-risks the Phase 3 program and the debt conversion removes a major overhang. Monitor for the Phase 3 protocol submission in Q3 2026, which will be the next catalyst. The strengthened balance sheet reduces near-term financing risk.
Price Chart
Executive Summary
Galectin Therapeutics reported Q2 2026 net loss of $9.2M ($0.14/share) vs $7.6M ($0.12/share) a year ago, but the headline is the FDA alignment on the Phase 3 trial design for belapectin in MASH cirrhosis and the conversion of $105.8M in debt to equity by Chairman Uihlein, eliminating a major liability and strengthening the balance sheet.
Key Financial Metrics
Key Facts
- FDA alignment on key elements of planned Phase 3 trial for belapectin in MASH cirrhosis with portal hypertension; registrational protocol submission expected in Q3 2026.
- Chairman Richard Uihlein converted $105.8M in debt and accrued interest into 34.4M shares of common stock, eliminating five of six credit facilities.
- Cash and cash equivalents of $13.2M as of June 30, 2026, with an additional $10M available under a line of credit; cash runway through June 2027.
- Net loss applicable to common stockholders was $9.2M ($0.14 per share) for Q2 2026 vs $7.6M ($0.12 per share) in Q2 2025.
- EPS of -$0.08 beat consensus of -$0.09 by 11.1%.
Financial Impact
Elimination of $105.8M in total debt ($91.0M principal + $14.8M accrued interest) via equity conversion; cash position $13.2M with runway through June 2027.
Risk Factors
- Clinical trial risk: Phase 3 may fail to meet endpoints despite FDA alignment.
- Dilution: 34.4M shares issued to Uihlein increase share count by ~52% from 65.9M shares outstanding.
- Cash runway only through June 2027; additional capital likely needed before Phase 3 completion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3345273 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 13, 2026 14d ago | DEFA14A | $3.69 | awaiting T+20 | — | $3.38 (−8.40%) |
Oct 13, 2026 14d ago | DEF 14A | $3.69 | awaiting T+20 | — | $3.38 (+8.40%) |
Oct 6, 2026 21d ago | Press Release | $3.76 | awaiting T+20 | — | $3.38 (−10.11%) |
Aug 14, 2026 10w ago | Press Release | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.38 (−1.74%) |
Aug 14, 2026 10w ago | 8-K | $3.44 $3.84 | ▲ +11.63% | ▲ +13.62% | $3.38 (−1.74%) |
Aug 4, 2026 12w ago | 8-K | $2.99 $4.17 | ▲ +39.46% | ▲ +40.70% | $3.38 (+13.04%) |
Jun 30, 2026 17w ago | Insider Cluster | $4.33 $3.49 | ▼ −19.40% | ▼ −17.21% | $3.38 (−21.94%) |
May 15, 2026 23w ago | Press Release | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.38 (+55.76%) |
May 15, 2026 23w ago | 8-K | $2.17 $2.62 | ▲ +20.74% | ▲ +18.62% | $3.38 (+55.76%) |
Apr 13, 2026 28w ago | EFFECT | $2.35 $2.21 | ▼ −5.96% | ▼ −13.69% | $3.38 (+43.83%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers